2017-005057-36: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and anticancer activity of GLG-801 in patients with Metastatic TNBC containing activated STAT3 (Phase II). |
|
|
| Ongoing | 1/2 | 80 | Europe | GLG-801, Tablet, Daraprim | GLG Pharma S.A., GLG Pharma S.A | Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal cell carcinoma or melanoma, Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal cell carcinoma or melanoma, Diseases [C] - Cancer [C04] | | | | |
